Uncategorized
Meet our product experts
Our panel of seasoned specialists provides deep knowledge and practical solutions to improve your product or process.
Menu
Our panel of seasoned specialists provides deep knowledge and practical solutions to improve your product or process.
Change Notifications Recombinant Insulin No display 2026 – Upcoming change in Insulin Human AF labels This change notification letter informs customers of the implementation of a revised label design for Insulin Human AF products. Download the full change notification:Download PDF 2026 – Update to the CEP for Benzalkonium Chloride This letter
Scale-up production, optimise processes, and increase cellular products yields with our Recombinant Insulin that’s approved by regulatory bodies worldwide.
Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership for the distribution of Benzalkonium Chloride in the United States of America.
Today Novo Nordisk Pharmatech announces the full year results for 2025 2025 was another important year for Novo Nordisk Pharmatech. We achieved solid revenue growth while continuing to invest in the long-term development of our company. With a net sale of 1,04 DKK billion we achieved a revenue growth of
Reduce resources needed for validation, improve process consistency and reduce costs due to contamination risk with our animal-free, recombinant TrypsiNNex®.
Webinar details January 29, 2026 The production of cell-based vaccines demands robust, contamination-free upstream processes to ensure product safety, regulatory compliance and manufacturing efficiency. However, identifying high-quality, animal-free raw materials that consistently perform across established cell systems remains a key challenge for vaccine manufacturers. In this webinar, we will present
Webinar details January 29, 2026 The production of cell-based vaccines demands robust, contamination-free upstream processes to ensure product safety, regulatory compliance and manufacturing efficiency. However, identifying high-quality, animal-free raw materials that consistently perform across established cell systems remains a key challenge for vaccine manufacturers. In this webinar, we will present
Københavnsvej 216
4600 Køge,
Denmark
+45 5667 1000
[email protected]
CVR-no. 13246149
